Alexion Optimistic Of Soliris' gMG Chances Despite Missing Ph III Target
Executive Summary
Alexion Pharmaceuticals Inc. is reassessing its regulatory strategy after Phase III data for its warhorse Soliris in myasthenia gravis, a rare neuromuscular disease, missed statistical significance on the primary endpoint but the company hopes regulators will give the therapy the benefit of the doubt after more data are generated.
You may also be interested in...
Stockwatch: ASCO Controversies
Despite the early sell-off in life science stocks during last week’s American Society for Clinical Oncology (ASCO) conference, there were some very positive new developments for cancer patients. The only problem now is the question of who will pay for combination treatment regimens.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.